The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Premiere SOLTI-2104
Previous Study | Return to List | Next Study

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05982093
Recruitment Status : Recruiting
First Posted : August 8, 2023
Last Update Posted : February 13, 2024
Sponsor:
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

Brief Summary:
PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.

Condition or disease Intervention/treatment Phase
Breast Cancer HER2-negative Breast Cancer Hormone Receptor Positive Tumor Premenopausal Breast Cancer Drug: Elacestrant Drug: Triptorelin Phase 2

Detailed Description:
PremiÈRe is a 4-week preoperative WOO randomized 2-arms study with a full program in correlative science, including an accurate estradiol measurement to evaluate the efficacy and biological activity of elacestrant in premenopausal patients with and without OFS (elacestrant 400mg per day during 28 days vs elacestrant at 400 mg per day during 28 days plus triptorelin 3.75mg i.m). Biological information (by tumor biopsy and /or blood sample) will be obtained at baseline, on day 14 (only blood) and day 28 post-treatment. Endpoints as rate of CCCA, mean reduction of Ki67 and estrogen-sensitive signature, allowing comparison of elacestrant activity across populations with and without OFS. Regarding the main objective, rate of CCCA, and considering the eligible population (ki67 between 10-35%) and unpublished data from ELIPSE study we estimate around a 20% of CCCA in all randomized patients. It's worthy to mention that a study using triptorelin as GnRH analog and GCMSMS for E2 measurement showed that nearly all women at day 14 (24 of out 26) had E2 levels in the postmenopausal range26, allowing us to compare groups with and without OFS at that early time-point.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized Pre-operative,Window of Opportunity Trial Investigating the Effect of Elacestrant With/Without Triptorelin in Premenopausal Patients With HR+/HER2- Breast Cancer - SOLTI-2104-PremiÈRe Trial.
Actual Study Start Date : October 3, 2023
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : January 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Elacestrant
without ovarian function suppression
Drug: Elacestrant
Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
Other Name: Orserdu

Active Comparator: Elacestrant + Triptorelin
with ovarian function suppression
Drug: Elacestrant
Elacestrant 400 mg given orally on a daily and continuous basis for 30 days or until the day before surgery or biopsy (+7 extra days).
Other Name: Orserdu

Drug: Triptorelin
Monthly triptorelin 3.75 mg powder and solvent for prolonged-release suspension for injection. Each vial contains 3.75 mg of triptorelin (acetate). After reconstitution with 2 ml of solvent, 1 ml of the suspension contains 1.875 mg triptorelin. This drug contains sodium, but less than 1 mmol (23 mg) of sodium per vial.Triptorelin will be administrated on D1 and D29.
Other Name: Orserdu




Primary Outcome Measures :
  1. To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC [ Time Frame: After 30 days (+7 days) of elacestrant therapy ]
    Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after 4 weeks of therapy.


Secondary Outcome Measures :
  1. To evaluate the biological activity of elacestrant with or without OFS in premenopausal women with ER+/HER2- operable EBC according to baseline research-based PAM50 subtype. [ Time Frame: After 30 days (+7 days) of elacestrant therapy ]
    Rate of CCCA determined by central assessment by IHC Ki67 (% Ki67 ≤ 2.7%) after short-term elacestrant therapy with or without OFS for patients Luminal A and Non-Luminal A.

  2. To evaluate the antiproliferative activity of elacestrant with or without OFS after -treatment [ Time Frame: After 30 days (+7 days) of elacestrant therapy ]
    Mean change in Ki67 measured by IHC Ki67 expression between pre- and post-treatment samples. - Differences in differential expression of proliferative genes

  3. To identify changes in the research-based PAM50 subtypes pre- and post-treatment samples after treatment [ Time Frame: After 30 days (+7 days) of elacestrant therapy ]
    Proportion of patients switching subtype between pre- and post-treatment samples

  4. To evaluate the effect of optimal and suboptimal OFS (E2 level greater than 2.72 pg/mL) in CCCA [ Time Frame: After 30 days (+7 days) of elacestrant therapy ]
    Mean change in measured by Ki67 expression between pre- and post-treatment samples and CCCA rate determined by Ki67 ≤ 2.7% between pre- and post-treatment samples of elacestrant therapy with or without OFS

  5. To evaluate levels of E2 in blood. [ Time Frame: After 14 days (+2 days) of elacestrant therapy ]
    Mean change of E2 levels between pre- and during treatment (D14) and pre-surgery samples

  6. To evaluate levels of FSH in blood. [ Time Frame: After 14 days (+2 days) of elacestrant therapy ]
    Mean change of FSH levels between pre- and during treatment (D14) and pre-surgery samples

  7. To evaluate the safety of the treatments when administered in pre-menopausal patient population. [ Time Frame: Until End of Study Visit (7-28 days after surgery)] ]
    Incidence and severity of adverse events, with severity, determined according to NCI CTAE v.5.0.

  8. To evaluate the tolerability of the treatments when administered in pre-menopausal patient population. [ Time Frame: Until End of Study Visit (7-28 days after surgery)] ]
    Change from baseline in targeted clinical laboratory test results, including ECGs



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent must be obtained prior to any trial-specific procedure.
  2. Female patients who are at least 35 years of age on the day of signing informed consent.
  3. Patient is premenopausal at the time of study entry

    Premenopausal status is defined as either:

    • Patient had last menstrual period within the last 6 months. OR
    • Plasma estradiol and FSH in the premenopausal range, according to local laboratory definition.

    Note: Patients who have undergone bilateral oophorectomy are not eligible.

  4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast untreated and recently diagnosed, with all the following characteristics:

    • Stage I to stage IIB operable breast cancer (7th Edition of the AJCC). Note: Axillary lymph node status must be assessed by fine needle biopsy or core biopsy. This procedure at screening will be omitted if there is no suspicion for positive axillary lymph node(s) radiographically or if a pathological report of suspicious lymph nodes of the results of a fine needle biopsy or core biopsy is available prior to the screening period.
    • Absence of distant metastasis (i.e., M0) as determined by institutional practice.
    • At least 1 lesion that can be accurately and serially measured in at least 1 dimension and for which the longest diameter is ≥ 10 mm as measured by magnetic resonance imaging (MRI) or ultrasound (US).
    • In the case of a multifocal tumor, the largest lesion must be ≥ 10 mm and designated the "target" lesion for all subsequent tumor evaluations. All biopsied tumors had to be ER+HER2-negative
  5. ER-positive with expression higher than 10% and HER2-negative tumor

    • HER2 negativity is defined as either of the following: Immunohistochemistry (IHC) 0, IHC 1+ or IHC2+/in situ hybridization (ISH) negative as per most recent American Society of Clinical Oncology (ASCO)-College of American Pathologists Guideline (CAP) guideline according to the local laboratory as determined on the most recently analyzed tissue sample.
    • Documentation of ER positive tumor with ≥ 10% staining by immunohistochemistry of cells as per most recent ASCO-CAP guideline according to the local laboratory determined on the most recently analyzed tissue sample, with or without progesterone receptor positivity.
  6. Ki67 expression ≥ 10% and ≤ 35% by local assessment
  7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  8. Breast cancer eligible for primary surgery.
  9. Availability of pre-treatment tumor tissue sample of FFPE tumor block from primary tumor for biomarker analysis. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for quality prior to enrollment. Archival tumor tissue or ex professo biopsy are acceptable.
  10. Adequate hematologic and organ function within 14 days before the first study treatment on Day 1, defined by the following:

    1. Neutrophils (ANC ≥1.000/μL).
    2. Hemoglobin ≥ 9.0 g/dL (with no need for transfusions).
    3. Platelet count ≥ 75. 000/μL.
    4. Serum creatinine ≤1.5 mg/dL or calculated creatinine clearance ≥30 mL/min (Cockcroft-Gault Equation)
    5. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN and activated partial thromboplastin time (aPTT) within therapeutic range.

      Note: Subjects who are receiving anticoagulation treatment which is monitored by INR (eg, warfarin) may be allowed to participate if they have a stable INR (ie, within therapeutic range) for at least 28 days prior to the first dose of study drug, in the absence of any exclusionary medical conditions, and provided that elacestrant would be appropriate therapy for the subject

    6. Potassium, total Calcium (corrected for serum albumin), and sodium NCI CTCAE v5.0 Grade ≤ 1.
    7. Alanine aminotransferase (ALT) ≤ 3x upper limit of normal (ULN)
    8. Aspartate aminotransferase (AST) ≤ 3x ULN
    9. Total bilirubin ≤ ULN or total bilirubin ≤ 1.5x ULN with direct bilirubin ≤ ULN of the laboratory in subjects with documented Gilbert's Syndrome
  11. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.
  12. Women of childbearing potential (CBP), defined as all women physiologically capable of becoming pregnant, must have confirmed negative serum pregnancy test within 7 days prior to randomization.
  13. Female subjects must not donate, or retrieve for their own use, oocytes from the time of screening and throughout the study treatment period, and for at least 120 days after the time of final study drug administration.
  14. Women of CBP must be willing to use highly effective methods of contraception. Contraception must continue during the trial treatment and after stopping the treatment received according to protocol. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Placement of a non-hormonal intrauterine device (IUD). Notes: Use of oral (estrogen and progesterone), transdermal, injected, implanted, hormone containing intrauterine system, or any other hormonal methods of contraception is not allowed in this trial. Women are considered of CBP unless: they have had ≥ 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e., age-appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least four weeks prior to randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment, she will be considered not of CBP. After the end of trial treatment, patients should use effective contraception at least until 28 days after therapy discontinuation.
  15. Patients must have the ability to swallow oral medication.

Exclusion Criteria:

  1. Inoperable locally advanced or inflammatory breast cancer (any stage III).
  2. Metastatic (Stage IV) breast cancer.
  3. Synchronous invasive bilateral or multicentric breast cancer.
  4. Patients requiring immediate neoadjuvant chemotherapy or immediate surgical intervention.
  5. Patients who have undergone sentinel lymph node biopsy or tumor excisional biopsy prior to study treatment.
  6. Prior malignancy within 3 years prior to randomization, except curatively treated non-melanoma skin cancer, in situ cancer or adequately and curatively treated Stage I or II cancer from which the patient is currently in complete remission.
  7. Patients currently on following medications, which cannot be interrupted 7 days prior treatment start:

    • Any prohibited medication as per decapeptyl (triptorelin) label
    • Strong inhibitors of CYP3A4, including grapefruit, grapefruit hybrids, pummelos, starfruit and Seville oranges
    • Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 (Refer to http://medicine.iupui.edu/clinpharm/ddis/) within 5 half-life of the drug prior to initiating trial therapy
    • Herbal preparations/medications. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng within 5 half-life of the drug prior to initiating trial therapy
    • Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
  8. Any treatment, local or systemic, including prior chemotherapy, ET, targeted therapy, and/or radiation therapy for the currently diagnosed BC prior to enrollment.
  9. Major surgical procedure or significant traumatic injury within 28 days prior to randomization.
  10. Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol.
  11. Any of the following within 6 months before enrollment: myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE v5.0 Grade ≥ 2, prolonged QTcF ≥ Grade 2 (i.e., > 480 msec), uncontrolled atrial fibrillation of any grade, coronary/peripheral artery bypass graft, heart failure ≥ Class II as defined by the New York Heart Association guidelines, or cerebrovascular accident including transient ischemic attack.
  12. Child-Pugh Score greater than Class A (i.e., score >6)
  13. Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism. However, subjects with the following conditions will be allowed to participate:

    1. Adequately treated catheter-related venous thrombosis occurring >28 days prior to the first dose of study drug
    2. Treatment with an anticoagulant, e.g., warfarin or heparin, for a thrombotic event occurring > 6 months before enrollment, or for an otherwise stable and allowed medical condition (eg, well controlled atrial fibrillation), provided dose and coagulation parameters (as defined by local standard of care) are in therapeutic range prior to the first dose of study drug and provided that an AI would be an appropriate therapy for the subject
  14. Known hypersensitivity to any of the study drugs, including excipients.
  15. Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications such as: uncontrolled nausea or vomiting (i.e., CTCAE ≥ Grade 3 despite antiemetic therapy), ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass.
  16. History of or clinical evidence of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent.
  17. Previous hormonal treatments for other indications such as osteoporosis, breast cancer prevention, hormonal substitutive therapy, such as raloxifene, tamoxifen, estrogen, progestins must have ended at least 12 months prior to trial registration. If a patient is on natural products known to contain progestins, they must be stopped 14 days prior to beginning study treatment.
  18. Used any prescription medication during the prior 1 month that the investigator judge is likely to interfere with the study or to pose an additional risk to the patient in participating.
  19. Female subject who is pregnant or breastfeeding or intends to become pregnant during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05982093


Contacts
Layout table for location contacts
Contact: Ruben Olivera, PhD + 34 933 436 302 ruben.olivera@gruposolti.org
Contact: Fernando Salvador, PhD + 34 933 436 302 fernando.salvador@gruposolti.org

Locations
Layout table for location information
Spain
Hospital Universitario Virgen de la Arrixaca Recruiting
El Palmar, Murcia, Spain
Contact: Ana Pérez       dm.oncoarrixaca@gmail.com   
Principal Investigator: Pilar Sánchez         
Hospital Universitari Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: Meritxell Bellet         
Principal Investigator: Meritxell Bellet         
Hospital Clinic de Barcelona Recruiting
Barcelona, Spain
Contact: Maria Vidal, MD         
Complejo Hospitalario San Pedro de Alcántara Recruiting
Cáceres, Spain, 10003
Contact: Santiago González, MD         
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain
Contact: Pablo Tolosa, MD         
Hospital Universitario Central de Asturias Recruiting
Oviedo, Spain
Contact: Yolanda Fernández         
Complejo Hospitalario de Navarra Recruiting
Pamplona, Spain
Principal Investigator: Susana De la Cruz         
Hospital Universitari General de Catalunya Recruiting
Sant Cugat Del Vallès, Spain
Contact: Vanesa Ortega         
Hospital Clínico de Valencia Recruiting
Valencia, Spain
Contact: Cristina Hernando, MD         
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Layout table for additonal information
Responsible Party: SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT05982093    
Other Study ID Numbers: PREMIERE (SOLTI-2104)
First Posted: August 8, 2023    Key Record Dates
Last Update Posted: February 13, 2024
Last Verified: February 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Triptorelin Pamoate
Luteolytic Agents
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptive Agents, Hormonal
Antineoplastic Agents, Hormonal
Antineoplastic Agents